Xeris Biopharma (XERS)

Executive Summary

Xeris Biopharma is a commercial-stage biopharmaceutical company leveraging its proprietary formulation technology to develop ready-to-use injectable and infusible therapies. The company has three approved products: Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous Cushing's syndrome. With a focus on endocrinology and neurology, Xeris addresses significant unmet needs in patient convenience and adherence. The company's valuation of approximately $1.2 billion reflects its commercial traction and pipeline potential, though it operates in competitive therapeutic areas. Xeris continues to expand its product reach through label expansions and geographic launches, positioning itself for sustained growth.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on sNDA for Recorlev in pediatric Cushing's syndrome70% success
• Q4 2026Topline results from Phase 3 trial of XP-2121 for congenital hyperinsulinism50% success
• Q2 2026European Commission approval for Gvoke auto-injector in pediatric hypoglycemia85% success